CTOs on the Move

Epizyme

www.epizyme.com

 
Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found, and then design small molecule therapeutic product candidates to inhibit the oncogene. The clinical development plan for each of our therapeutic product candidates is directed towards patients with a particular genetically defined cancer. Our approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.epizyme.com
  • 400 Technology Sq 4th Floor
    Cambridge, MA USA 02139
  • Phone: 617.229.5872

Executives

Name Title Contact Details

Funding

Epizyme raised $100M on 11/07/2019

Similar Companies

Brain Corporation

Brain Corp is a software technology company specializing in the development of intelligent, autonomous systems. Brain Corp`s A.I. technology represents the next generation of artificial brains for self-driving vehicles (SDVs). We`re building brains for robots, and turning today`s manually-operated machines into tomorrow`s autonomous solutions.

ABI Inc

ABI Inc is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Templates

Molecular Templates is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers. Our Engineered Toxin Bodies (ETBs) platform represent a new class of targeted biologic therapies that possess unique biological properties.

Meiogen Biotechnology Corporation

Meiogen Biotechnology Corporation is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CereVasc

The CereVasc eShuntâ„¢ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.